多组学整合分析预测2型糖尿病合并早期慢性肾脏病患者的eGFR轨迹
本研究基于多国前瞻性PROVALID队列的基线血浆样本,对258例eGFR稳定者和223例eGFR快速下降者进行加速病例对照分析,使用贝叶斯多变量逻辑回归评估402个候选标志物对eGFR轨迹的判别能力。结果显示,KIM-1和基线eGFR是eGFR轨迹的重要预测因素,而代谢组和脂质组标志物未显著改善判别,全部变量模型的AUC仅为0.63。
要点
- KIM-1是预测早期糖尿病肾病eGFR快速下降的最重要蛋白标志物。
- 加入代谢组和脂质组标志物未显著提升对eGFR轨迹的判别能力。
- 在基线eGFR保留的患者中,对eGFR轨迹的判别能力仅为中等(AUC 0.63)。
核心结论
- 在基线eGFR保留的早期糖尿病肾病患者中,KIM-1是eGFR轨迹最重要的预测标志物,但整体判别能力中等。
研究设计与样本
- 基于PROVALID前瞻性队列的基线血浆样本,采用加速病例对照设计,纳入258例eGFR稳定者和223例eGFR快速下降者,中位随访35个月。
主要发现
- 稳定组中位eGFR变化为0.1 mL/min/year,快速下降组中位eGFR下降为-6.75 mL/min/year。
- 在402个候选预测因子中,KIM-1和NT-proBNP是与eGFR轨迹相关的蛋白标志物,基线eGFR为重要临床协变量。
- 代谢组和脂质组标志物未显著改善判别,全部变量模型的AUC为0.63,与仅用KIM-1和基线eGFR的模型统计上无差异。
关键数值与推荐
- 基线中位eGFR为84 mL/min/1.73 m2,中位尿白蛋白肌酐比为8.1 mg/g。
临床怎么用
- 对于基线eGFR保留的早期糖尿病肾病患者,可考虑检测血浆KIM-1辅助评估eGFR下降风险。
- 不应依赖代谢组或脂质组标志物来显著提升eGFR轨迹的预测能力。
局限性
- 对eGFR轨迹的判别能力仅为中等(AUC 0.63)。
- 代谢组和脂质组标志物未显著改善判别。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clinical risk factors explain only a fraction of the variability of estimated glomerular filtration rate (eGFR) decline in people with type 2 diabetes. Cross-omics technologies by virtue of a wide spectrum screening of plasma samples have the potential to identify biomarkers for the refinement of prognosis in addition to clinical variables. Here we utilized proteomics, metabolomics and lipidomics panel assay measurements in baseline plasma samples from the multinational PROVALID study (PROspective cohort study in patients with type 2 diabetes mellitus for VALIDation of biomarkers) of patients with incident or early chronic kidney disease (median follow-up 35 months, median baseline eGFR 84 mL/min/1.73 m2, urine albumin-to-creatinine ratio 8.1 mg/g). In an accelerated case-control study, 258 individuals with a stable eGFR course (median eGFR change 0.1 mL/min/year) were compared to 223 individuals with a rapid eGFR decline (median eGFR decline -6.75 mL/min/year) using Bayesian multivariable logistic regression models to assess the discrimination of eGFR trajectories. The analysis included 402 candidate predictors and showed two protein markers (KIM-1, NTproBNP) to be relevant predictors of the eGFR trajectory with baseline eGFR being an important clinical covariate. The inclusion of metabolomic and lipidomic platforms did not improve discrimination substantially. Predictions using all available variables were statistically indistinguishable from predictions using only KIM-1 and baseline eGFR (area under the receiver operating characteristic curve 0.63). Thus, the discrimination of eGFR trajectories in patients with incident or early diabetic kidney disease and maintained baseline eGFR was modest and the protein marker KIM-1 was the most important predictor.
引用
- Kammer M, Heinzel A, Willency JA, et al. Integrative analysis of prognostic biomarkers derived from multiomics panels helps discrimination of chronic kidney disease trajectories in people with type 2 diabetes. Kidney Int. 2019. PMID: 31679767. doi:10.1016/j.kint.2019.07.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。